Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis
Simon Witzel, André Maier, Robert Steinbach, et al.
JAMA Neurology (2022) Vol. 79, Iss. 2, pp. 121-121
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Amyotrophic lateral sclerosis
Eva L. Feldman, Stephen A. Goutman, Susanne Petri, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1363-1380
Open Access | Times Cited: 562
Antioxidant Therapeutic Strategies in Neurodegenerative Diseases
Constanza Morén, Ruth Mary deSouza, Darly Milena Giraldo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9328-9328
Open Access | Times Cited: 76
Current State and Future Directions in the Therapy of ALS
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt, et al.
Cells (2023) Vol. 12, Iss. 11, pp. 1523-1523
Open Access | Times Cited: 59
Revitalizing Ancient Mitochondria with Nano‐Strategies: Mitochondria‐Remedying Nanodrugs Concentrate on Disease Control
Xingyu Long, Min Liu, Yayun Nan, et al.
Advanced Materials (2024) Vol. 36, Iss. 18
Closed Access | Times Cited: 31
TDP-43-stratified single-cell proteomics of postmortem human spinal motor neurons reveals protein dynamics in amyotrophic lateral sclerosis
Amanda J. Guise, Santosh A. Misal, Richard H. Carson, et al.
Cell Reports (2024) Vol. 43, Iss. 1, pp. 113636-113636
Open Access | Times Cited: 23
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, et al.
Drugs (2022) Vol. 82, Iss. 13, pp. 1367-1388
Closed Access | Times Cited: 64
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JingSi Jiang, Yan Wang, Min Deng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 50
Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases
Yuqi Fu, Jin Zhang, Rui Qin, et al.
Pharmacological Reviews (2025), pp. 100053-100053
Closed Access | Times Cited: 1
Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
Benjamin Rix Brooks, James Berry, Malgorzata Ciepielewska, et al.
EClinicalMedicine (2022) Vol. 52, pp. 101590-101590
Open Access | Times Cited: 37
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
Alberto Nascè, Karim Gariani, François R. Jornayvaz, et al.
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1131-1131
Open Access | Times Cited: 29
Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
Christina N. Fournier
Neurotherapeutics (2022) Vol. 19, Iss. 4, pp. 1180-1192
Open Access | Times Cited: 29
Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis
Hongmei Du, Zijun Huo, Yanchun Chen, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 971-971
Open Access | Times Cited: 20
Advances in antioxidant nanozymes for biomedical applications
Xinlin Liu, Hongwei Xu, Houlin Peng, et al.
Coordination Chemistry Reviews (2023) Vol. 502, pp. 215610-215610
Closed Access | Times Cited: 17
Edaravone alleviated allergic airway inflammation by inhibiting oxidative stress and endoplasmic reticulum stress
Guiping Zhu, Yingying Zeng, Wenjun Peng, et al.
European Journal of Pharmacology (2024) Vol. 966, pp. 176317-176317
Closed Access | Times Cited: 8
Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment
Arsh Haj Mohamad Ebrahim Ketabforoush, Faezeh Faghihi, Fereshteh Azedi, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 7, pp. 495-512
Closed Access | Times Cited: 8
Optimal Therapeutic Strategy of Bone Marrow-Originated Autologous Mesenchymal Stromal/Stem Cells for ALS
Seung Hyun Kim, Ki‐Wook Oh, Min‐Young Noh, et al.
Stem Cells Translational Medicine (2024) Vol. 13, Iss. 4, pp. 309-316
Open Access | Times Cited: 7
Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis
Jingshuang Yan, Huixin Chen, Yan Zhang, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 7
Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis
Gary L. Pattee, Angela Genge, Philippe Couratier, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 10, pp. 859-866
Open Access | Times Cited: 16
Why should we care about astrocytes in a motor neuron disease?
Katarina Stoklund Dittlau, Ludo Van Den Bosch
Frontiers in Molecular Medicine (2023) Vol. 3
Open Access | Times Cited: 15
Therapeutic targeting ofALSpathways: Refocusing an incomplete picture
Nicholas J. Maragakis, Mamede de Carvalho, Michael D. Weiss
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 11, pp. 1948-1971
Open Access | Times Cited: 15
Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis
Priya Singh, Paul Belliveau, Jennifer Towle, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e258-e267
Closed Access | Times Cited: 6
AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice
Hsin‐Hsiung Chen, Hsin-Tung Yeo, Yun‐Hsin Huang, et al.
Skeletal Muscle (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
Keiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
EClinicalMedicine (2022) Vol. 53, pp. 101707-101707
Open Access | Times Cited: 22
Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
Anas Zakarya Nourelden, Ibrahim Kamal, Abdulrahman Ibrahim Hagrass, et al.
Neurological Sciences (2023) Vol. 44, Iss. 10, pp. 3429-3442
Open Access | Times Cited: 12
Current Small Molecule–Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics
Nitesh Sanghai, Billy Vuong, Ahmet Burak Berk, et al.
ChemMedChem (2024) Vol. 19, Iss. 9
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top